We are honored to welcome Dr. Katharine Knobil to our Board of Directors! She has more than 20 years of experience in #biopharma research and development with expertise in #oncology and #immunology. Learn more about this exciting phase of growth here: nimbustx.com/2024/03/12/nim…
Nimbus Therapeutics
@NimbusTx
We integrate computational chemistry and other advanced technologies to design breakthrough medicines and transform drug development. bit.ly/2DThNVN
119 Following 1.8K Followers 398 Posts
Latest posts 5
On this #VeteransDay, we salute the brave individuals who have served our nation with honor and courage. Thank you for your sacrifice and dedication to safeguarding our freedom.
Exciting news: @NewEnglandVC has nominated Nimbus for the 2023 NEVY Award for ‘Powerhouse Life Science Company of the Year'. Congratulations to our team, and we’re looking forward to celebrating all the #NEVYs23 nominees next month. bit.ly/47qltbD
Another impactful day at #SITC23 as Nimbus' David Ciccone presented preclinical data on our #HPK1 inhibitor, which support the potential for best-in-class selectivity among publicly disclosed HPK1 inhibitor programs to date. More on our Ph1/2 HPK1 program: bit.ly/3Mt9txQ
Today at #SITC23 we presented positive preliminary dose escalation data from our Ph 1/2 #HPK1 trial, showing monotherapy benefit in 3/13 evaluable patients, including complete response in 1 patient & prolonged stable disease in 2 patients. View our poster: bit.ly/3FI3q4H